Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25